Lunai Bioworks Inc. (LNAI): Nasdaq/NYSE listing notice — Enochian BioSciences receives Nasdaq notice for delayed Form 10-Q filing and amends convertible notes

February 16, 2023, the Company received a notice (the “ Notice ”) from The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended December 31, 2022 (the “ Form 10-Q ”), the Company remains in non-compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the Securities and Exchange Commission. As previously disclosed on Form 8-Ks filed with the Securities and Exchange Commission, on October 17, 2022 and November 23, 2022, respectively, the Co

On February 16, 2023, the Company amended and restated those two certain convertible promissory notes between the Company and Paseco ApS (the “ Holder ”) dated February 6, 2020, each in the principal amount of $600,000 (the “ February Notes ”) by entering into two amended and restated secured convertible promissory notes, each with an effective date of December 30, 2022 and each in the principal amount of $600,000 (the “ Amended and Restated February Notes ”).

On February 16, 2023, the Company amended that certain promissory note dated March 30, 2020 in the principal amount of $5,000,000 between the Company and the Holder (the “ March Note ”).

On February 16, 2023, the Company entered into a security agreement between the Company and the Holder, effective as of December 30, 2022 (the “ Security Agreement ”) under which the Company pledged and granted the Holder a first priority security interest in and lien upon all of the Company’s wholly-owned assets as collateral security for the prompt payment in full of the principal amounts of the February Notes and the March Note when due.